In MPM, two such candidate target TAAs are currently being investigated in clinical trials: mesothelin, which is overexpressed on the tumor cells, and fibroblast activation protein (FAP) that is overexpressed on tumor stromal cells. The gene discussed is MSLN; the disease is neoplasm.